1.0Lanco Medical Grouphttps://lancomedicalgroup.com/eslmgrouphttps://lancomedicalgroup.com/es/author/lmgroup/rich600338<blockquote class="wp-embedded-content" data-secret="0Ek27ICsTJ"><a href="https://lancomedicalgroup.com/es/lmg/">ametralladora ligera</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://lancomedicalgroup.com/es/lmg/embed/#?secret=0Ek27ICsTJ" width="600" height="338" title="«LMG» — Lanco Medical Group" data-secret="0Ek27ICsTJ" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://lancomedicalgroup.com/wp-includes/js/wp-embed.min.js </script>PORTAFOLIO ACCESO PAISES NOSOTROS CONTACTO PORTAFOLIO ACCESO PAISES NOSOTROS CONTACTO The partner that transforms specialized portfolios into institutional access Lanco Medical Group connects manufacturers and specialized portfolios with institutional channels, tenders, and regional pharmaceutical execution in Central America and the Caribbean Explore capabilities Regional presence 6 Active Countries 144M+ Units 2025 69% Institutional Channel +12 Years in Operation Regional growth requires more than distribution Most distributors compete in saturated markets, without access institutional nor specialized regulatory infrastructure The Problem Low-margin portfolios  — Many regional distributors continue to compete only in traditional generics, where the margins and growth are increasingly limited. Institutional tenders out of reach — CSS, CCSS, IGSS, IHSS, ISSS, and SeNaSa concentrate a large part of the regional market and require experience operational, institutional relationships, and capacity to execution. RTCA regulatory complexity —  Registering products in multiple markets requires specialized teams, regulatory monitoring, and regional operational structure. Our 3 Pillars Access to specialized molecules Biosimilars, biologics, anticoagulants, oncology, neurology and next-generation therapies with implementation active institutional Regional institutional infrastructure — Active experience in institutional access, management of key accounts and specialized pharmaceutical execution. Specialized regulatory managementRTCA coordination, maintenance of active records and regulatory support for generics, biosimilars, and specialized therapies. The Problem Our 3 Pillars Specialized portfolio by therapeutic area Anticoagulants and Hematology Leadership in hemophilia treatments in Costa Rica and active institutional access in CSS, CCSS, and IGSS. Oncology and Biosimilars Biosimilars from international manufacturers with experience in RTCA regulatory management and institutional bidding. Cardiovascular Portfolio with active presence in public and private channels throughout the region. Diabetes and Metabolism Priority access to institutional programs for chronic diseases in strategic markets. Neurology Experience in hospital protocols, chronic management, and specialized therapies. High Specialty and Biologicals Biologics and specialized therapies with regulatory support, qualified distribution, and clinical follow-up. Cases, results, and regional recognition More than regional presence, we build sustained institutional access in strategic markets of Central America and the Caribbean +12 Years in Operation 6 Active Countries 144M+ Units 2025 69% Institutional Channel Largest institutional contract awarded in our therapeutic area — CCSS Costa Rica. Leadership in hemophilia treatment in Costa Rica. Active regional operation in 6 markets institutional Distributor of the Year — U.S. Happy Workers Award — Panama. Entrepreneur of the Year (USA) Active institutional presence inCentral America and the Caribbean Direct regional access — We do not operate thru agents. external agents Guatemala IGSS — Guatemalan Social Security Institute Sustained growth in specialized portfolios. Honduras IHSS — Honduran Social Security Institute Active institutional access and specialized commercial force. Dominican Republic SeNaSa — National Health Insurance Institutional expansion in one of the Caribbean markets with the greatest potential. El Salvador El Salvador ISSS — Salvadoran Social Security Institute Institutional coverage and active private channel. Costa Rica CCSS — Costa Rican Social Security Fund Our most relevant institutional contract and leadership in hemophilia. Panama CSS — Social Security Fund Regional operational hub with public and private coverage We are Lanco Medical Group For more than 12 years, we have built institutional relationships, regulatory infrastructure, and specialized execution in Central America and the Caribbean. Lanco Medical Group operates as a specialized regional platform for high-value pharmaceutical portfolios. high-value pharmaceuticals. We do not compete as a traditional generic distributor. We integrate institutional access, support regulatory, specialized distribution, and regional commercial execution.144 million units distributed in 2025 represent patients attended to, active institutions, and real execution capacity. Part of the LMG Bio Lifesciences ecosystem, connecting global pharmaceutical manufacturers with Latin America. A regional infrastructure Two models of alliance We work with regional distributors and pharmaceutical manufacturers international under models of collaboration adapted to each operational structure I am a regional distributor Expand your portfolio with specialized high-value molecules. high value. Discover:Which molecules are compatible with your current network.How does joint institutional access work?What RTCA regulatory support is included.What commercial structure allows competition in channelsinstitutional. No generic proposals. No commitments before understanding their operation. Explore opportunities for distributors I’m an international manufacturer Evaluate how to institutionally enter Central America and the Caribbean. We analyze:Regional distribution and access capacity institutional.Active RTCA records and available regulatory support.Institutional history and bidding experience.Operational structure, timelines, and needs regulatory for your molecule. This isn’t a commercial pitch. It’s a strategic capabilities assessment. Request strategic evaluation I want more information Submit Contact Us ‎+1 (561) 437-2450 info@lancomedicalgroup.com Regional pharmaceutical execution Real institutional access Lanco Medical Group · info@lancomedicalgroup.com · www.lancomedicalgroup.com Panamá · Costa Rica · Guatemala · Honduras · El Salvador · República Dominicana República Dominicana Guatemala Panamá El Salvador Honduras Costa Rica México Guatemala República Dominicana Panamá El Salvador Honduras Costa Rica México Guatemala República Dominicana Lanco Medical Group © 2026 – All rights reserved.https://lancomedicalgroup.com/wp-content/uploads/2026/04/LMG-blanco.png720390